SOURCE: Bolton Medical

Bolton Medical

April 07, 2014 15:27 ET

Bolton Medical Announces First Post-Approval Study Case Completed Using the Relay® Thoracic Stent-Graft

SUNRISE, FL--(Marketwired - Apr 7, 2014) - Bolton Medical announced today that treatment of the first Post-Approval Study patient in the United States with the new Relay Thoracic Stent-Graft with Plus Delivery System has been successfully completed.

The procedure took place at Fairfield Medical Center in Lancaster, Ohio and was performed by Krishna Mannava, MD, FACS, RPVI, Director Vascular Services.

"We had a great outcome in a high risk patient with difficult anatomy. I feel the design of the coaxial delivery system, and the Bolton Medical Relay Stent- Graft itself, facilitates precise placement and conformability in both conventional and complex TEVAR procedures," said Dr. Mannava.

Specifically designed for the thoracic aorta, the Relay Stent-Graft is offered in a wide range of sizes to accommodate many different anatomies of patients with thoracic aortic aneurysms and penetrating atherosclerotic ulcers.

The new Relay Thoracic Stent-Graft is paired with the unique four-step Plus Delivery System that allows for easier navigation and the ability to achieve precise placement in a variety of anatomies.


Bolton Medical currently manufactures Relay and Relay NBS Thoracic Stent-Grafts. These devices are used worldwide for the treatment of thoracic aortic pathologies. To date, more than 11,000 Relay and Relay NBS Thoracic Stent-Grafts have been implanted worldwide. Bolton Medical is a private company, with European operations based in Barcelona, Spain and U.S. operations in Sunrise, Florida. Bolton Medical is a wholly-owned subsidiary of the Werfen Life Group, a diverse manufacturer and supplier of products for the medical industry.

For more information on Relay Thoracic Stent-Graft with Plus Delivery System, please visit

Contact Information